Abstract 12267: Efficacy and Safety of Alirocumab in Statin-Intolerant Patients Over 3 Years: Open-Label Extension of the ODYSSEY ALTERNATIVE Trial

Patrick M Moriarty,Paul D Thompson,Christopher P Cannon,John R Guyton,Jean Bergeron, Franklin J Zieve,Eric Bruckert,Terry A Jacobson,Marie T Baccara-Dinet,Jian Zhao, Stephen Donahue,Shazia Ali,Robert Pordy,Daniel A Gipe

Circulation（2018）

引用 22|浏览23

暂无评分

摘要

Background: The 24-week randomized, double-blind (DB) ODYSSEY ALTERNATIVE (NCT01709513) trial demonstrated significant LDL-C reductions with the PCSK9 inhibitor alirocumab versus ezetimibe in stati...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要